Within European cancer registration areas, there is a substantial variation in testicular cancer incidence, with a ratio around a factor 10 between the highest rates registered in Switzerland, Denmark and Norway, and the lowest ones in Southern Italy, Spain and Eastern countries. Part of the variation is possibly due to registration accuracy, since the differences were lower in relation to mortality, and the pattern was somewhat different, the highest rates being observed in East Germany, Hungary and Czechoslovakia, and the lowest ones in Greece, Portugal and Spain (Levi et al., 1989) . The main reason for the elevated mortality in Eastern countries is however the lack of availability of efficacious treatment, particularly cisplatinum, which have substantially reduced mortality over the last decade (Osterlind, 1986; Boyle et al., 1990) , although the time trends in various countries were somewhat different even before the identification of efficacious chemotherapy. On the other hand, the disease is uniformly rare in Black populations, whether in Africa or USA (Schottenfeld et al., 1980 ; Van den Eeden & Weiss, 1989) .
The age curve of the disease has two peaks, one in the twenties and one later in life (Clemmesen, 1968) , following the relative frequency of different histological types (since teratomas have an earlier peak incidence than the more frequent seminomas, and lymphomas are more frequent at older ages) and possibly reflecting the role of different risk factors (Boyle et al., 1987; Pike et al., 1987) . Further, there is evidence that the incidence is now increasing predominantly in young men, and specifically for teratomas (Boyle et al., 1987) .
Cryptorchidism is the only one established risk factor for the disease, with relative risks of the order of 2-4, not restricted to the retrieved testis, and a population attributable risk of approximately 10% in North America (Schottenfeld et al., 1980; Pottern et al., 1985; Motris Brown et al., 1987; Strader et al., 1988) . Further, the disease is more frequent in higher social classes (Davies, 1981) . Other potential factors, such as in utero exposure to oestrogens, or occupational exposure to farming or chemical substances, and marital status have been studied (Ross et al., 1979; Beard et al., 1984; Mills et al., 1984; Newell et al., 1987; Pearce et al., 1987; Bernstein et al., 1988; Levi et al., 1988) , but there is at present no clear evidence on their role nor on their potential impact on the increase of the disease.
In order to present further documentation on the descriptive epidemiology of testicular cancer, we present in this article incidence and survival data for the Cancer Registry of the Canton of Vaud, Switzerland. This is one of the cancer registration areas with highest incidence rates on European and global scale (Levi et al., 1989) .
The (Levi, 1987 The overall age-standardised (world standard) incidence rate was 8.4/100,000 (4.1 seminoma; 3.6 teratoma; 0.7 other and clinical), and the truncated 15-44 years was 15.8 (7.3 seminoma; 7.6 teratoma; 0.9 other and clinical). The peak rate for all histotypes together (over 25/100,000) was reached in the 25-34 age groups, and occurred earlier for teratomas than for seminomas. After declining to a bottom rate of 1.2/100,000 in the 60-64 year age group, some increase (chiefly due to lymphomas and other histotypes) was observed at older ages.
Rates for the Lausanne conurbation (accounting for about 40% of the population of the whole Canton) were about 60% higher than rural ones (10.7 vs 6.8/100,000, all ages; 18.1 vs 12.9 at ages 15-54). Most of the difference was accounted for by teratoma alone, rates for seminoma being similar in urban and rural areas.
Trends in age-standardised incidence rates over the 14-year calendar period considered are shown in Table I , and 3-year moving averages for all testicular cancers at all ages and truncated 15-44 years are plotted in Figure 1 . Overall incidence remained stable in relation both to the overall rates and to the younger age groups. There was some inconsistent rise in seminomas and 'other' histotypes, and some decline in teratomas, but this can be easily accounted for by random variation alone.
Overall 5-year survival rates increased from 73 to 87% between 1974-80 and 1981-87 (X2 = 7.56, P <0.01) ( Figure  2 ). Survival improved for seminomas from 84 to 95%, for teratomas from 68 to 86% and for other histotypes from 32 to 54%.
Some of the results from this study are well established, such as the bimodal incidence curve of testicular cancer with an earlier and major peak in the second to third decade, the younger age distribution for teratomas than for seminomas, the higher rates in urban than in rural areas, and the im-F. LEVI et al. proved survival over more recent calendar periods (Clemmesen, 1968; 0sterlind, 1986; Boyle et al., 1987 Boyle et al., , 1990 .
The major and original finding from this study is however the absence of any trend in incidence over the past decades, together with the fact that the rates registered in this population (8.4/100,000) were higher than in other published series. In comparison, age-adjusted registered incidence rates in the early 1980s were 3.8 in American Whites (Morris Brown et al., 1986) , approximately 5 in Scotland (Boyle et al., 1987) and 8.0 in Denmark, after a steady rise from 3.1/100,000 in 1943-47 (Clemmesen, 1968; Osterlind, 1986) . The peak in age-specific rates was just over 10 in South Thames, England, as compared to 25 in Vaud. Only rates of blacks from the Surveillance, Epidemiology and End Results (SEER) Program appeared stable from 1973 to 1984, but an increase of about a third of testicular cancer incidence in white Americans was registered over the same calendar period (Van Den Eeden & Weiss, 1989) .
This seems therefore to be the first well monitored white population where stable rates in testicular cancer incidence have been observed, and it is thus tempting to speculate whether an asymptote in the rise in testicular cancer will be reached in other white populations in the near future.
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